Can you identify keytruda's initial fda approved cancer indication?

What was Keytruda’s first FDA-approved cancer indication?

Keytruda (pembrolizumab) received its initial FDA approval for unresectable or metastatic melanoma that has progressed after either ipilimumab (Yervoy) or anti–CTLA-4 therapy (or both), including those who have progressed after prior therapy [1].

When did that initial approval happen?

The FDA’s first approval of Keytruda for that indication occurred in 2014 [1].

How does that first indication relate to later broader uses?

That early melanoma approval was later expanded through additional trials and FDA label updates to cover other cancers and biomarker-defined settings. Those later changes do not affect the original starting indication described above [1].

Sources:
[1] https://www.drugpatentwatch.com/p/keytruda-pembrolizumab/